[go: up one dir, main page]

IN2013MU01782A - - Google Patents

Download PDF

Info

Publication number
IN2013MU01782A
IN2013MU01782A IN1782MU2013A IN2013MU01782A IN 2013MU01782 A IN2013MU01782 A IN 2013MU01782A IN 1782MU2013 A IN1782MU2013 A IN 1782MU2013A IN 2013MU01782 A IN2013MU01782 A IN 2013MU01782A
Authority
IN
India
Prior art keywords
rasagiline
enantiomer
disease
salts
pharmaceutical compositions
Prior art date
Application number
Inventor
Sushrut Krishnaji Kulkarni
Pavak Rajnikanth Mehta
Ritesh Kapoor
Original Assignee
Cadila Healthcare Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Cadila Healthcare Ltd filed Critical Cadila Healthcare Ltd
Priority to PCT/IN2014/000336 priority Critical patent/WO2014192022A1/en
Priority to IN1782MU2013 priority patent/IN2013MU01782A/en
Publication of IN2013MU01782A publication Critical patent/IN2013MU01782A/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia

Landscapes

  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Engineering & Computer Science (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Epidemiology (AREA)
  • Psychology (AREA)
  • Hospice & Palliative Care (AREA)
  • Psychiatry (AREA)
  • Medicinal Preparation (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)

Abstract

The present invention provides pharmaceutical compositions of rasagiline, its enantiomer or salts thereof. In particular, the invention relates to stabilizer free pharmaceutical compositions of rasagiline, its enantiomer or salts thereof, process of preparation of such compositions and use thereof for treatment of Parkinson’s disease, dementia and Alzheimer’s disease.
IN1782MU2013 2013-05-20 2014-05-20 IN2013MU01782A (en)

Priority Applications (2)

Application Number Priority Date Filing Date Title
PCT/IN2014/000336 WO2014192022A1 (en) 2013-05-20 2014-05-20 Pharmaceutical compositions of rasagiline
IN1782MU2013 IN2013MU01782A (en) 2013-05-20 2014-05-20

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
IN1782MU2013 IN2013MU01782A (en) 2013-05-20 2014-05-20

Publications (1)

Publication Number Publication Date
IN2013MU01782A true IN2013MU01782A (en) 2015-06-26

Family

ID=51300794

Family Applications (1)

Application Number Title Priority Date Filing Date
IN1782MU2013 IN2013MU01782A (en) 2013-05-20 2014-05-20

Country Status (2)

Country Link
IN (1) IN2013MU01782A (en)
WO (1) WO2014192022A1 (en)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN118356414A (en) * 2023-01-19 2024-07-19 上海云晟研新生物科技有限公司 Rasagiline mesylate orodispersible film composition, preparation method and application thereof

Family Cites Families (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IL111240A (en) * 1993-10-18 2001-10-31 Teva Pharma Salts of r(+) - enantiomers of n- propargyl-1-aminoindan and pharmaceutical compositions comprising them
JP2008507586A (en) * 2004-07-26 2008-03-13 テバ ファーマシューティカル インダストリーズ リミティド Pharmaceutical administration containing rasagrine
EP1892233A1 (en) * 2006-08-18 2008-02-27 Ratiopharm GmbH New salts of the active component rasagiline
CN1911211B (en) * 2006-08-25 2010-04-14 重庆医药工业研究院有限责任公司 Solid oral preparation of leishajilan
EP1987816A1 (en) * 2007-04-30 2008-11-05 Ratiopharm GmbH Adsorbate of a rasagiline salt with a water-soluble inactive ingredient
WO2009122301A2 (en) * 2008-03-31 2009-10-08 Actavis Group Ptc Ehf Rasagiline mesylate particles and process for the preparation thereof
US20100041920A1 (en) * 2008-07-18 2010-02-18 Stephen Benedict David Winter New salt forms of an aminoindan derivative
WO2010111264A2 (en) * 2009-03-24 2010-09-30 Dr. Reddy's Laboratories Ltd. Rasagiline formulations
ES2503015T3 (en) * 2009-07-09 2014-10-06 Ratiopharm Gmbh Rasagiline salts and their pharmaceutical preparations
WO2011010324A1 (en) * 2009-07-23 2011-01-27 Alkem Laboratories Ltd. Oral pharmaceutical composition of rasagiline and process for preparing thereof
WO2011080589A2 (en) * 2009-12-30 2011-07-07 Actavis Group Ptc Ehf Solid state forms of rasagiline salts
CN102791258B (en) * 2010-02-03 2018-05-08 图必制药公司 Alleviating prolongation delivery formulations of Rasagiline and application thereof
WO2011121607A2 (en) * 2010-03-29 2011-10-06 Cadila Healthcare Limited Rasagiline and its pharmaceutically acceptable salts
EP2389927A1 (en) * 2010-05-30 2011-11-30 Abdi Ibrahim Ilac Sanayi ve Ticaret Anonim Sirketi Pharmaceutical formulations of rasagiline
WO2012153349A2 (en) * 2011-05-04 2012-11-15 Cadila Healthcare Limited Rasagiline and its pharmaceutically acceptable salts
ES2502140T1 (en) * 2013-02-06 2014-10-02 Galenicum Health S.L. Rasagiline hemitartrate immediate-release tablets

Also Published As

Publication number Publication date
WO2014192022A1 (en) 2014-12-04

Similar Documents

Publication Publication Date Title
MX2017005834A (en) Aadc polynucleotides for the treatment of parkinson's disease.
PH12016501307A1 (en) Compounds
WO2015085318A3 (en) Targeted adaptive vaccines
MX2017008136A (en) L-tartrate salt of pridopidine.
IL252091A0 (en) 2-amino-3,5-difluoro-3,6-dimethyl-6-phenyl-3,4,5,6-tetrahydropyridines as bace1 inhibitors for treating alzheimer’s disease
BR112017007063A2 (en) compositions and methods for treating insomnia
PH12016500814A1 (en) Heteroaryl butanoic acid derivatives
NZ753881A (en) Treatment of neurological diseases
MY180844A (en) Solid pharmaceutical compositions comprising biopterin derivatives and uses of such compositions
PH12016501686A1 (en) Pharmaceutical compositions of sitagliptin
BR112016028316A2 (en) oral pharmaceutical composition of isotretinoin, its preparation process and treatment method
BR112016022575A2 (en) COMPOSITIONS AND METHODS FOR THE TREATMENT OF NEURODEGENERATIVE DISEASES
IN2014CH00840A (en)
PH12017500923A1 (en) New dosage and use of a a2a antagonist
PL3352742T3 (en) Compositions comprising triterpenoids for the treatment of alzheimer's disease and parkinson's disease
IN2013MU01782A (en)
IL265656A (en) Compositions and methods for treating alzheimer's disease and parkinson's disease
IN2013MU02576A (en)
IN2014MU00495A (en)
ZA201801945B (en) Compositions and methods for the treatment of parkinson's disease
DK3148588T3 (en) N,n-bis-2-mercaptoethyl isophthalamide for the treatment of parkinson's disease
IN2014MU00276A (en)
EP3085691A4 (en) Method for preparing the anhydrous crystalline form of isoniazid-derived hydrazone, thus produced crystalline polymorph of the anhydrous form, use thereof for the treatment of alzheimer's disease, parkinsonism and other neurodegenerative disorders, and pharmaceutical composition
HK40012465A (en) Compositions and methods for treating alzheimer's disease and parkinson's disease
AU2015904411A0 (en) Compositions and methods for the treatment of Alzheimer's disease